Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

USA Antimicrobial Susceptibility Testing Market to Reach USD 1.8 Billion by 2035, Driven by Rising Antimicrobial Resistance and Diagnostic Innovation

accessnewswire.com
TMO Thermo Fisher Scientific is mentioned as a leading player in the growing US antimicrobial susceptibility testing market, driven by rising AMR and diagnostic innovation. The company is investing in advanced platforms, indicating positive market prospects. BDX Becton, Dickinson and Company is identified as a key player in the expanding US antimicrobial susceptibility testing market. The company's focus on rapid and reliable solutions aligns with market drivers like AMR and diagnostic innovation. DHR Danaher Corporation is listed as a leading company in the US antimicrobial susceptibility testing market, which is projected to grow significantly. Their involvement in providing advanced AST platforms suggests a positive outlook. BIO Bio-Rad Laboratories is recognized as a key participant in the growing US antimicrobial susceptibility testing market. The company's focus on diagnostic solutions aligns with the increasing demand driven by antimicrobial resistance.

USA Antimicrobial Susceptibility Testing Market to Reach USD 1.8 Billion by 2035, Driven by Rising Antimicrobial Resistance and Diagnostic Innovation USA antimicrobial susceptibility testing market is characterized by the presence of leading diagnostics and life sciences companies focused on delivering rapid, reliable, and scalable solutions.

NEWARK, DE / ACCESS Newswire / April 1, 2026 / Demand for antimicrobial susceptibility testing in the USA is entering a steady growth phase, projected to expand from USD 1.3 billion in 2025 to USD 1.8 billion by 2035, registering a CAGR of 3.4%, according to Future Market Insights (FMI). The market's expansion is primarily driven by the escalating threat of antimicrobial resistance (AMR), increasing incidence of hospital-acquired infections (HAIs), and the growing need for precise, data-driven treatment decisions in modern healthcare systems.

AST plays a critical role in determining the effectiveness of antibiotics against specific pathogens, enabling clinicians to prescribe targeted therapies, reduce misuse of antibiotics, and improve patient outcomes. As healthcare systems across the United States prioritize precision medicine and infection control strategies, AST is becoming an essential diagnostic tool across hospitals, diagnostic laboratories, and research institutions.

Get Access of Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-29643

Antimicrobial Susceptibility Testing Market in the USA - Quick Stats Snapshot

2025 Market Value: USD 1.3 Billion

2035 Forecast Value: USD 1.8 Billion

CAGR (2025-2035): 3.4%

Leading Product Segment: Instruments (40% share)

Key Applications: Sepsis, Respiratory Infections (18% share)

Key Growth Regions: West USA (3.9%), South USA (3.5%), Northeast USA (3.1%), Midwest USA (2.7%)

Market Momentum: Rising AMR Threat and Demand for Precision Diagnostics

The increasing prevalence of antibiotic-resistant infections is a major public health concern in the United States, with millions of cases reported annually. AST is at the forefront of combating this crisis by enabling timely identification of effective antimicrobial therapies.

Healthcare providers are increasingly integrating AST into antimicrobial stewardship programs to ensure responsible antibiotic use. Additionally, structural shifts such as increased healthcare investments, expansion of diagnostic infrastructure, and rising awareness of AMR are supporting the sustained adoption of AST solutions nationwide.

Technological advancements are further accelerating market growth. Automated systems, rapid diagnostic platforms, and molecular testing techniques are significantly improving turnaround times, accuracy, and efficiency of AST processes, making them more viable for routine clinical use.

Segment Intelligence: Instruments and Sepsis Applications Lead Demand

In terms of product segmentation, instruments dominate the AST market, accounting for approximately 40% share. These automated systems are essential for delivering rapid, high-throughput, and accurate results in clinical laboratories, supporting improved workflow and reduced human error.

From an application perspective, sepsis represents the leading segment due to its high mortality risk and urgent need for timely intervention. AST enables clinicians to quickly determine the most effective antibiotic therapy in sepsis cases, significantly improving survival rates. Respiratory infections also contribute notably, accounting for around 18% of the market demand.

Regional Outlook: West USA Leads Growth with Strong Diagnostic Infrastructure

Regionally, the West USA is expected to witness the fastest growth, with a projected CAGR of 3.9%, driven by advanced healthcare infrastructure, strong presence of research institutions, and early adoption of diagnostic innovations.

The South USA follows closely with a CAGR of 3.5%, supported by expanding healthcare facilities and rising infection rates. The Northeast USA, with its dense population and high healthcare spending, continues to show stable growth at 3.1%, while the Midwest USA reflects moderate expansion at 2.7%.

Across all regions, increasing focus on antimicrobial stewardship and precision medicine is reinforcing the demand for AST technologies.

Competitive Landscape: Innovation, Speed, and Accuracy Define Market Leadership

The USA antimicrobial susceptibility testing market is characterized by the presence of leading diagnostics and life sciences companies focused on delivering rapid, reliable, and scalable solutions. Competitive differentiation is driven by:

Speed and accuracy of diagnostic results

Automation and workflow integration

Breadth of pathogen and antibiotic testing coverage

Data management and reporting capabilities

Strong distribution and after-sales support networks

Key players operating in the market include:

Thermo Fisher Scientific

BD (Becton, Dickinson and Company)

Danaher Corporation

Bio-Rad Laboratories

Creative Diagnostics

These companies are actively investing in advanced AST platforms, including automated and rapid testing systems, to meet the growing demand from hospitals and clinical laboratories.

Strategic Takeaways for Stakeholders

Prioritize development of rapid and automated AST solutions

Strengthen integration with antimicrobial stewardship programs

Expand presence across high-growth regions such as West and South USA

Focus on improving diagnostic accuracy and turnaround time

Invest in scalable and cost-effective testing platforms for broader adoption

Why This Market Matters Now

With antimicrobial resistance posing a growing threat to global public health, the importance of precise and timely diagnostic solutions has never been greater. Antimicrobial susceptibility testing is emerging as a cornerstone of modern infection management, enabling targeted therapies and supporting sustainable antibiotic use.

As the U.S. healthcare system continues to evolve toward precision medicine and data-driven care, the AST market represents a stable, mission-critical, and innovation-driven opportunity over the next decade.

For an in-depth analysis of market dynamics, competitive benchmarking, and future outlook, stakeholders are encouraged to explore the full report by Future Market Insights.

For an in-depth analysis of market dynamics, competitive benchmarking, and the complete strategic outlook for the Demand for Antimicrobial Susceptibility Testing in USA through 2035, Full Report Request: https://www.futuremarketinsights.com/reports/united-states-antimicrobial-susceptibility-testing-market

Browse More Reports:

Antimicrobial Susceptibility Testing Market: https://www.futuremarketinsights.com/reports/antibiotic-susceptibility-testing-market

Antibiotic Susceptibility Testing Devices Market: https://www.futuremarketinsights.com/reports/antibiotic-susceptibility-testing-devices-market

Demand for Antimicrobial Susceptibility Testing in Japan: https://www.futuremarketinsights.com/reports/japan-antimicrobial-susceptibility-testing-market

Demand for MRSA Testing in USA: https://www.futuremarketinsights.com/reports/united-states-mrsa-testing-market

Demand for Hemostasis Testing Systems in USA: https://www.futuremarketinsights.com/reports/united-states-hemostasis-testing-systems-market

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Delaware, USA, with a global delivery center in India and offices in the UK and UAE, FMI delivers actionable insights to businesses across industries including automotive, technology, consumer products, manufacturing, energy, and chemicals.

An ESOMAR-certified research organization, FMI provides custom and syndicated market reports and consulting services, supporting both Fortune 1,000 companies and SMEs. Its team of 300+ experienced analysts ensures credible, data-driven insights to help clients navigate global markets and identify growth opportunities.

For Press & Corporate Inquiries

Rahul Singh

AVP - Marketing and Growth Strategy

Future Market Insights, Inc.

+91 8600020075

For Sales - [email protected]

SOURCE: Future Market Insights, Inc.